

CARDIOVASCULAR

PRODUCT	SPECS	EDMF(CTD)	USDMF	CEP
RAMIPRIL	IP / BP / EP / USP	CEP 2009-083	19714	R1-CEP 2009-083-REV 04
QUINAPRIL HCl	EP / USP	CEP 2016-100	19413	R0-CEP 2016-100-REV 01
BENAZEPRIL HCl	EP / USP	CEP 2011-197	20097	R1-CEP 2011-197-REV 00
PERINDOPRIL TERT-BUTYLAMINE	EP / BP / USP	CEP 2013-245		R1-CEP 2013-245-REV 01
PERINDOPRIL ARGININE	INHOUSE	√	21866	
RANOLAZINE	INHOUSE	√		
ENALAPRIL MALEATE	EP			
TICAGRELOR	EP / BP			

ANTI ASTHAMATIC

BUDESONIDE	IP / BP / EP / USP	CEP 2006-295	20609	R1-CEP 2006-295-REV 03
BAMBUTEROL HCl	IP / EP / BP	√		
R - SALBUTAMOL SULPHATE	IP / INHOUSE	√		
LEVALBUTEROL HCl	USP	√	20557	
SALMETEROL XINAFOATE	IP / EP / BP	CEP 2008-239	22054	R1-CEP 2008-239-REV 03
IPRATROPIUM BROMIDE	IP / EP / BP	CEP 2008-150	21179	R1-CEP 2008-150-REV 02
CICLESONIDE	EP / INHOUSE	CEP 2014-090	23650	R1-CEP 2014-090-REV 00
FLUTICASONE PROPIONATE	IP / BP / EP / USP	CEP 2007-262	22980	R1-CEP 2007-262-REV 02
FLUTICASONE FUROATE	EP	√	33955	
MOMETASONE FUROATE MONOHYDRATE	EP	CEP 2018-303	23977	R0-CEP 2018-303-REV 01
FORMOTEROL FUMARATE	EP / BP / USP	CEP 2013-220		R1-CEP 2013-220-REV 01
MONTELUKAST SODIUM	IP / BP / EP / USP	*		

ANTI CANCER

BICALUTAMIDE	EP / USP	CEP 2012-223	20502	R1-CEP 2012-223-REV 00
IFOSFAMIDE	IP / BP / EP / USP	CEP 2022-146	25081	APPLIED
IFOSFAMIDE STERILE	IP / BP / EP / USP	√		
CYCLOPHOSPHAMIDE	IP / BP / EP / USP	√		
CYCLOPHOSPHAMIDE STERILE	IP / BP / EP / USP	CEP 2021-209	35313	APPLIED
MESNA	EP / BP / USP	CEP 2009-127	22664	R1-CEP 2009-127-REV 00
MERCAPTOPURINE	IP / BP / EP / USP	CEP 2021-275	22971	APPLIED
AZATHIOPRINE	BP / EP / USP	CEP 2014-030	23038	R1-CEP 2014-030-REV 00
ENZALUTAMIDE	USP	√	35969	
NILOTINIB	INHOUSE	√		
PALBOCICLIB	INHOUSE	*		
IBRUTINIB	INHOUSE	*		

ANTI COAGULANT

APIXABAN	INHOUSE	√	35969	
RIVAROXABAN	INHOUSE / EP	*		

OVERACTIVE BLADDER

MIRABEGRON	INHOUSE			
------------	---------	--	--	--

- Products protected by patents are developed solely for the R&D purposes intended to support regulatory submissions.
- It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).
- Intermediates of above API's will be available.

* Validation batches completed DMF under compilation.

For Enquiries:

Tel : +91-22-69436100

E-mail : api@aartipharmalabs.com

URL : www.aartipharmalabs.com

ANTI DIABETIC

PRODUCT	SPECS	EDMF(CTD)	USDMF	CEP
SITAGLIPTIN HCl	INHOUSE	√		
SITAGLIPTIN PHOSPHATE MONOHYDRATE	IP / BP / EP / USP	*		
SITAGLIPTIN PHOSPHATE ANHYDROUS	INHOUSE	√		
CANAGLIFLOZIN	INHOUSE	*		
DAPAGLIFLOZIN	INHOUSE	*		
EMPAGLIFLOZIN	INHOUSE	*		

ARTHRITIS

TOFACITINIB CITRATE	INHOUSE	*
APREMILAST	INHOUSE	

CNS AGENT

VENLAFAXINE HCl	BP / EP / USP	CEP 2006-183	19879	R1-CEP 2006-183-REV 02
VENLAFAXINE HCl POLYMORPH B	EP / USP	CEP 2009-082	28433	R1-CEP 2009-082-REV 01
QUETIAPINE FUMARATE	EP / USP	CEP 2019-291	21336	RO-CEP 2019-291-REV 00
BUPROPION HCl	EP / BP / USP	√	27204	
DULOXETINE HCl	EP			

SKIN CARE

MOMETASONE FUROATE ANHYDROUS	IP / BP / EP / USP	CEP 2007-302	21334	R1-CEP 2007-302-REV 02
DESONIDE	INHOUSE	√	22963	
ADAPALENE	BP / EP / USP	CEP 2022-158	22709	APPLIED

CALCIMIMETIC

CINACALCET	IP / INHOUSE	√
------------	--------------	---

DECONGESTANT

PHENYLEPHERINE	IP / BP / EP / USP	√
----------------	--------------------	---

ANTI THALASSAEMIC

DEFERIPRONE	INHOUSE	√
DEFERASIROX	EP	*

ANALGESIC

DIFLUNISAL	USP	√	24762
------------	-----	---	-------

OPHTHALMOLOGIC

LOTEPREDNOL ETABONATE	INHOUSE	√	26249
OLOPATADINE HCl	USP	√	

UPCOMING MOLECULES

PRODUCT NAME	THERAPEUTIC CATEGORIES	PRODUCT NAME	THERAPEUTIC CATEGORIES
VENETOCLAX	ANTI CANCER	RIBOCICLIB	ANTI CANCER
APALUTAMIDE	ANTI CANCER	VORTIOXETINE HBr	CNS AGENT
OSIMERTITNIB	ANTI CANCER	EDOXBAN TOSYLATE	ANTI COAGULANT
PAZOPANIB	ANTI CANCER	OLMESARTAN	CARDIOVASCULAR
RUXOLITINIB	ANTI CANCER	ELAGOLIX	ENDOMETRIOSIS & UTERINE FIBROIDS
OLAPARIB	ANTI CANCER		

XANTHINE DERIVATIVES

• CAFFEINE • AMINOPHYLLINE • ETOPHYLLINE • THEOPHYLLINE

- Products protected by patents are developed solely for the R&D purposes intended to support regulatory submissions.
- It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).
- Intermediates of above API's will be available.

* Validation batches completed DMF under compilation.